Erratum: ANKRD44 Gene Silencing: A Putative Role in Trastuzumab Resistance in Her2-Like Breast Cancer
- Frontiers Media SA, Lausanne, Switzerland
by La Ferla, M., Lessi, F., Aretini, P., Pellegrini, D., Franceschi, S., Tantillo, E., et al. (2019). Front. Oncol. 9:547. doi: 10.3389/fonc.2019.00547
Due to a production error, the affiliation for Antonio G. Naccarato was incorrectly given as the “Department of Cell and Developmental Biology, the Hebrew University of Jerusalem, Jerusalem, Israel” (affiliation 8). The correct affiliation is the “Department of Translational Research and New Technologies in Medicine and Surgery, University Hospital of Pisa, Pisa, Italy” (affiliation 10).
The publisher apologizes for this mistake. The original article has been updated.
Keywords: Her2+ breast cancer, Trastuzumab resistance, ANKRD44, next generation sequencing, LC-MS/MS, gene silencing
Citation: Frontiers Production Office (2019) Erratum: ANKRD44 Gene Silencing: A Putative Role in Trastuzumab Resistance in Her2-Like Breast Cancer. Front. Oncol. 9:709. doi: 10.3389/fonc.2019.00709
Received: 16 July 2019; Accepted: 16 July 2019;
Published: 18 July 2019.
Approved by:Frontiers Editorial Office, Frontiers Media SA, Switzerland
Copyright © 2019 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, firstname.lastname@example.org